Salarius Pharmaceuticals Files 8-K
Ticker: DCOY · Form: 8-K · Filed: Jul 25, 2024 · CIK: 1615219
Sentiment: neutral
Topics: 8-K, corporate-filing, pharmaceuticals
TL;DR
Salarius Pharma filed an 8-K on 7/25/24, standard corporate update.
AI Summary
Salarius Pharmaceuticals, Inc. filed an 8-K on July 25, 2024, reporting other events and financial statements. The company, formerly known as Flex Pharma, Inc., is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing indicates ongoing corporate activity and reporting requirements for Salarius Pharmaceuticals, Inc., providing transparency to investors.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports significant corporate events or financial updates.
Key Numbers
- 001-36812 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5087339 — IRS Employer Identification Number (Tax identification number for the company.)
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- Flex Pharma, Inc. (company) — Former company name
- July 25, 2024 (date) — Date of report
- 2450 Holcombe Blvd. Suite X Houston, TX 77021 (address) — Principal executive offices
FAQ
What specific "Other Events" are being reported in this 8-K filing?
The provided text does not detail the specific "Other Events" beyond listing it as an item information category.
What is the significance of the "Financial Statements and Exhibits" being filed?
This indicates that the company is providing updated financial information or related documents as required by the SEC.
When did Salarius Pharmaceuticals, Inc. change its name from Flex Pharma, Inc.?
The date of the name change was July 30, 2014.
What is the primary business of Salarius Pharmaceuticals, Inc. according to its SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where are Salarius Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 2450 Holcombe Blvd. Suite X, Houston, TX 77021.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-07-25 17:03:14
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
- $335,921 — vering the registered offering of up to $335,921 of shares of common stock, par value $0
Filing Documents
- flks-20240725.htm (8-K) — 29KB
- slrx-ex51opiniontoprospect.htm (EX-5.1) — 15KB
- image_0.jpg (GRAPHIC) — 27KB
- 0001615219-24-000068.txt ( ) — 207KB
- flks-20240725.xsd (EX-101.SCH) — 2KB
- flks-20240725_lab.xml (EX-101.LAB) — 22KB
- flks-20240725_pre.xml (EX-101.PRE) — 13KB
- flks-20240725_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On July 25, 2024, Salarius Pharmaceuticals, Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") to its effective registration statement on Form S-3 (File No. 333-266589) (the "Registration Statement"), filed with the U.S. Securities and Exchange Commission on August 5, 2022 and declared effective by the SEC on August 16, 2022, covering the registered offering of up to $335,921 of shares of common stock, par value $0.0001 per share, of the Company (the "Shares"), pursuant to the At the Market Offering Agreement, dated as of February 5, 2021, with Ladenburg Thalmann & Co. Inc. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Hogan Lovells US LLP, relating to the validity of the Shares being registered, which opinion is attached as Exhibit 5.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Hogan Lovells US LLP 23.1 Consent of Hogan Lovells US LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: July 25, 2024 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Chief Financial Officer